Better yield of (18)fluorodeoxyglucose-positron emission tomography in patients with metastatic differentiated thyroid carcinoma during thyrotropin stimulation
To determine whether (18)fluorodeoxyglucose-positron emission tomography (FDG-PET) for the detection of recurrences or metastases of differentiated thyroid carcinoma should be performed during thyrotropin (TSH) suppression or TSH stimulation, eight patients were studied sequentially. After the secon...
Gespeichert in:
| Veröffentlicht in: | Thyroid (New York, N.Y.) N.Y.), 2002-05, Vol.12 (5), p.381-387 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 387 |
|---|---|
| container_issue | 5 |
| container_start_page | 381 |
| container_title | Thyroid (New York, N.Y.) |
| container_volume | 12 |
| creator | van Tol, Karin M Jager, Pieter L Piers, D Albertus Pruim, Jan de Vries, Elisabeth G E Dullaart, Robin P F Links, Thera P |
| description | To determine whether (18)fluorodeoxyglucose-positron emission tomography (FDG-PET) for the detection of recurrences or metastases of differentiated thyroid carcinoma should be performed during thyrotropin (TSH) suppression or TSH stimulation, eight patients were studied sequentially. After the second FDG-PET scan, a therapeutic (131)I dose was administered with posttherapy scans obtained 10 days later. Both FDG-PET scans were compared with each other and with the (131)I posttherapy whole body scans by two independent observers. Findings were verified using other imaging modalities or biopsies. Median TSH was 0.04 mU/L during TSH suppression and 64 mU/L during TSH stimulation. The FDG-PET scans during TSH suppression showed abnormalities in four patients and the FDG-PET scan during TSH stimulation in five patients. One patient was only positive during TSH stimulation. In two other patients the FDG-PET scan during TSH stimulation clearly identified more lesions, and in all positive patients lesion contrast was better during TSH stimulation. In two patients FDG-PET findings during TSH stimulation led to a change in clinical management. Thus, the performance of FDG-PET during TSH stimulation was either superior or equal to FDG-PET during TSH suppression, but never inferior. To detect metastatic or recurrent differentiated thyroid carcinoma FDG-PET should be performed during hypothyroidism, leading to TSH stimulation. |
| doi_str_mv | 10.1089/105072502760043459 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_71878267</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>71878267</sourcerecordid><originalsourceid>FETCH-LOGICAL-p207t-333630b7e66e012052e552e2636aa2a9bb7b69cacc9b03415e59d5b978843b163</originalsourceid><addsrcrecordid>eNo1ULtOxDAQdAHijscPUCBXCIqAHcd2XMKJl3QSDdSRnWzujJI42I4gX8OvYnRHsdrVzOysZhE6p-SGklLdUsKJzDnJpSCkYAVXB2j5B2YJFQt0HMIHIVSUkh2hBc2JklSVS_RzDzGCx7OFrsGuxVe0vG67yXnXgPueN91UuwDZ6IKN3g0YehuCTUN0vdt4PW5nbAc86mhhiAF_2bjFPUQdYoJq3Ni2BZ8oqyM0OG5n72yDa-1rO7he42bydtjsiHRhTGYh2n7q0robTtFhq7sAZ_t-gt4fH95Wz9n69elldbfOxpzImDHGBCNGghBAUjqeA0-VCya0zrUyRhqhal3XyhBWUA5cNdwoWZYFM1SwE3S58x29-5wgxCrlrKHr9ABuCpWkpSxzIZPwYi-cTA9NNXrbaz9X_y9lvzyefA4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71878267</pqid></control><display><type>article</type><title>Better yield of (18)fluorodeoxyglucose-positron emission tomography in patients with metastatic differentiated thyroid carcinoma during thyrotropin stimulation</title><source>Mary Ann Liebert Online Subscription</source><source>MEDLINE</source><creator>van Tol, Karin M ; Jager, Pieter L ; Piers, D Albertus ; Pruim, Jan ; de Vries, Elisabeth G E ; Dullaart, Robin P F ; Links, Thera P</creator><creatorcontrib>van Tol, Karin M ; Jager, Pieter L ; Piers, D Albertus ; Pruim, Jan ; de Vries, Elisabeth G E ; Dullaart, Robin P F ; Links, Thera P</creatorcontrib><description>To determine whether (18)fluorodeoxyglucose-positron emission tomography (FDG-PET) for the detection of recurrences or metastases of differentiated thyroid carcinoma should be performed during thyrotropin (TSH) suppression or TSH stimulation, eight patients were studied sequentially. After the second FDG-PET scan, a therapeutic (131)I dose was administered with posttherapy scans obtained 10 days later. Both FDG-PET scans were compared with each other and with the (131)I posttherapy whole body scans by two independent observers. Findings were verified using other imaging modalities or biopsies. Median TSH was 0.04 mU/L during TSH suppression and 64 mU/L during TSH stimulation. The FDG-PET scans during TSH suppression showed abnormalities in four patients and the FDG-PET scan during TSH stimulation in five patients. One patient was only positive during TSH stimulation. In two other patients the FDG-PET scan during TSH stimulation clearly identified more lesions, and in all positive patients lesion contrast was better during TSH stimulation. In two patients FDG-PET findings during TSH stimulation led to a change in clinical management. Thus, the performance of FDG-PET during TSH stimulation was either superior or equal to FDG-PET during TSH suppression, but never inferior. To detect metastatic or recurrent differentiated thyroid carcinoma FDG-PET should be performed during hypothyroidism, leading to TSH stimulation.</description><identifier>ISSN: 1050-7256</identifier><identifier>DOI: 10.1089/105072502760043459</identifier><identifier>PMID: 12097198</identifier><language>eng</language><publisher>United States</publisher><subject>Adult ; Aged ; Female ; Fluorodeoxyglucose F18 - pharmacokinetics ; Humans ; Iodine Radioisotopes - therapeutic use ; Male ; Middle Aged ; Neoplasm Metastasis - diagnostic imaging ; Prospective Studies ; Radiopharmaceuticals - pharmacokinetics ; Stimulation, Chemical ; Thyroid Neoplasms - diagnostic imaging ; Thyroid Neoplasms - pathology ; Thyroid Neoplasms - radiotherapy ; Thyrotropin - blood ; Thyrotropin - pharmacology ; Tissue Distribution ; Tomography, Emission-Computed ; Whole-Body Counting</subject><ispartof>Thyroid (New York, N.Y.), 2002-05, Vol.12 (5), p.381-387</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27922,27923</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12097198$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>van Tol, Karin M</creatorcontrib><creatorcontrib>Jager, Pieter L</creatorcontrib><creatorcontrib>Piers, D Albertus</creatorcontrib><creatorcontrib>Pruim, Jan</creatorcontrib><creatorcontrib>de Vries, Elisabeth G E</creatorcontrib><creatorcontrib>Dullaart, Robin P F</creatorcontrib><creatorcontrib>Links, Thera P</creatorcontrib><title>Better yield of (18)fluorodeoxyglucose-positron emission tomography in patients with metastatic differentiated thyroid carcinoma during thyrotropin stimulation</title><title>Thyroid (New York, N.Y.)</title><addtitle>Thyroid</addtitle><description>To determine whether (18)fluorodeoxyglucose-positron emission tomography (FDG-PET) for the detection of recurrences or metastases of differentiated thyroid carcinoma should be performed during thyrotropin (TSH) suppression or TSH stimulation, eight patients were studied sequentially. After the second FDG-PET scan, a therapeutic (131)I dose was administered with posttherapy scans obtained 10 days later. Both FDG-PET scans were compared with each other and with the (131)I posttherapy whole body scans by two independent observers. Findings were verified using other imaging modalities or biopsies. Median TSH was 0.04 mU/L during TSH suppression and 64 mU/L during TSH stimulation. The FDG-PET scans during TSH suppression showed abnormalities in four patients and the FDG-PET scan during TSH stimulation in five patients. One patient was only positive during TSH stimulation. In two other patients the FDG-PET scan during TSH stimulation clearly identified more lesions, and in all positive patients lesion contrast was better during TSH stimulation. In two patients FDG-PET findings during TSH stimulation led to a change in clinical management. Thus, the performance of FDG-PET during TSH stimulation was either superior or equal to FDG-PET during TSH suppression, but never inferior. To detect metastatic or recurrent differentiated thyroid carcinoma FDG-PET should be performed during hypothyroidism, leading to TSH stimulation.</description><subject>Adult</subject><subject>Aged</subject><subject>Female</subject><subject>Fluorodeoxyglucose F18 - pharmacokinetics</subject><subject>Humans</subject><subject>Iodine Radioisotopes - therapeutic use</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neoplasm Metastasis - diagnostic imaging</subject><subject>Prospective Studies</subject><subject>Radiopharmaceuticals - pharmacokinetics</subject><subject>Stimulation, Chemical</subject><subject>Thyroid Neoplasms - diagnostic imaging</subject><subject>Thyroid Neoplasms - pathology</subject><subject>Thyroid Neoplasms - radiotherapy</subject><subject>Thyrotropin - blood</subject><subject>Thyrotropin - pharmacology</subject><subject>Tissue Distribution</subject><subject>Tomography, Emission-Computed</subject><subject>Whole-Body Counting</subject><issn>1050-7256</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1ULtOxDAQdAHijscPUCBXCIqAHcd2XMKJl3QSDdSRnWzujJI42I4gX8OvYnRHsdrVzOysZhE6p-SGklLdUsKJzDnJpSCkYAVXB2j5B2YJFQt0HMIHIVSUkh2hBc2JklSVS_RzDzGCx7OFrsGuxVe0vG67yXnXgPueN91UuwDZ6IKN3g0YehuCTUN0vdt4PW5nbAc86mhhiAF_2bjFPUQdYoJq3Ni2BZ8oqyM0OG5n72yDa-1rO7he42bydtjsiHRhTGYh2n7q0robTtFhq7sAZ_t-gt4fH95Wz9n69elldbfOxpzImDHGBCNGghBAUjqeA0-VCya0zrUyRhqhal3XyhBWUA5cNdwoWZYFM1SwE3S58x29-5wgxCrlrKHr9ABuCpWkpSxzIZPwYi-cTA9NNXrbaz9X_y9lvzyefA4</recordid><startdate>20020501</startdate><enddate>20020501</enddate><creator>van Tol, Karin M</creator><creator>Jager, Pieter L</creator><creator>Piers, D Albertus</creator><creator>Pruim, Jan</creator><creator>de Vries, Elisabeth G E</creator><creator>Dullaart, Robin P F</creator><creator>Links, Thera P</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20020501</creationdate><title>Better yield of (18)fluorodeoxyglucose-positron emission tomography in patients with metastatic differentiated thyroid carcinoma during thyrotropin stimulation</title><author>van Tol, Karin M ; Jager, Pieter L ; Piers, D Albertus ; Pruim, Jan ; de Vries, Elisabeth G E ; Dullaart, Robin P F ; Links, Thera P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p207t-333630b7e66e012052e552e2636aa2a9bb7b69cacc9b03415e59d5b978843b163</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Female</topic><topic>Fluorodeoxyglucose F18 - pharmacokinetics</topic><topic>Humans</topic><topic>Iodine Radioisotopes - therapeutic use</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neoplasm Metastasis - diagnostic imaging</topic><topic>Prospective Studies</topic><topic>Radiopharmaceuticals - pharmacokinetics</topic><topic>Stimulation, Chemical</topic><topic>Thyroid Neoplasms - diagnostic imaging</topic><topic>Thyroid Neoplasms - pathology</topic><topic>Thyroid Neoplasms - radiotherapy</topic><topic>Thyrotropin - blood</topic><topic>Thyrotropin - pharmacology</topic><topic>Tissue Distribution</topic><topic>Tomography, Emission-Computed</topic><topic>Whole-Body Counting</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>van Tol, Karin M</creatorcontrib><creatorcontrib>Jager, Pieter L</creatorcontrib><creatorcontrib>Piers, D Albertus</creatorcontrib><creatorcontrib>Pruim, Jan</creatorcontrib><creatorcontrib>de Vries, Elisabeth G E</creatorcontrib><creatorcontrib>Dullaart, Robin P F</creatorcontrib><creatorcontrib>Links, Thera P</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Thyroid (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>van Tol, Karin M</au><au>Jager, Pieter L</au><au>Piers, D Albertus</au><au>Pruim, Jan</au><au>de Vries, Elisabeth G E</au><au>Dullaart, Robin P F</au><au>Links, Thera P</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Better yield of (18)fluorodeoxyglucose-positron emission tomography in patients with metastatic differentiated thyroid carcinoma during thyrotropin stimulation</atitle><jtitle>Thyroid (New York, N.Y.)</jtitle><addtitle>Thyroid</addtitle><date>2002-05-01</date><risdate>2002</risdate><volume>12</volume><issue>5</issue><spage>381</spage><epage>387</epage><pages>381-387</pages><issn>1050-7256</issn><abstract>To determine whether (18)fluorodeoxyglucose-positron emission tomography (FDG-PET) for the detection of recurrences or metastases of differentiated thyroid carcinoma should be performed during thyrotropin (TSH) suppression or TSH stimulation, eight patients were studied sequentially. After the second FDG-PET scan, a therapeutic (131)I dose was administered with posttherapy scans obtained 10 days later. Both FDG-PET scans were compared with each other and with the (131)I posttherapy whole body scans by two independent observers. Findings were verified using other imaging modalities or biopsies. Median TSH was 0.04 mU/L during TSH suppression and 64 mU/L during TSH stimulation. The FDG-PET scans during TSH suppression showed abnormalities in four patients and the FDG-PET scan during TSH stimulation in five patients. One patient was only positive during TSH stimulation. In two other patients the FDG-PET scan during TSH stimulation clearly identified more lesions, and in all positive patients lesion contrast was better during TSH stimulation. In two patients FDG-PET findings during TSH stimulation led to a change in clinical management. Thus, the performance of FDG-PET during TSH stimulation was either superior or equal to FDG-PET during TSH suppression, but never inferior. To detect metastatic or recurrent differentiated thyroid carcinoma FDG-PET should be performed during hypothyroidism, leading to TSH stimulation.</abstract><cop>United States</cop><pmid>12097198</pmid><doi>10.1089/105072502760043459</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1050-7256 |
| ispartof | Thyroid (New York, N.Y.), 2002-05, Vol.12 (5), p.381-387 |
| issn | 1050-7256 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_71878267 |
| source | Mary Ann Liebert Online Subscription; MEDLINE |
| subjects | Adult Aged Female Fluorodeoxyglucose F18 - pharmacokinetics Humans Iodine Radioisotopes - therapeutic use Male Middle Aged Neoplasm Metastasis - diagnostic imaging Prospective Studies Radiopharmaceuticals - pharmacokinetics Stimulation, Chemical Thyroid Neoplasms - diagnostic imaging Thyroid Neoplasms - pathology Thyroid Neoplasms - radiotherapy Thyrotropin - blood Thyrotropin - pharmacology Tissue Distribution Tomography, Emission-Computed Whole-Body Counting |
| title | Better yield of (18)fluorodeoxyglucose-positron emission tomography in patients with metastatic differentiated thyroid carcinoma during thyrotropin stimulation |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T12%3A52%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Better%20yield%20of%20(18)fluorodeoxyglucose-positron%20emission%20tomography%20in%20patients%20with%20metastatic%20differentiated%20thyroid%20carcinoma%20during%20thyrotropin%20stimulation&rft.jtitle=Thyroid%20(New%20York,%20N.Y.)&rft.au=van%20Tol,%20Karin%20M&rft.date=2002-05-01&rft.volume=12&rft.issue=5&rft.spage=381&rft.epage=387&rft.pages=381-387&rft.issn=1050-7256&rft_id=info:doi/10.1089/105072502760043459&rft_dat=%3Cproquest_pubme%3E71878267%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=71878267&rft_id=info:pmid/12097198&rfr_iscdi=true |